Litcius/Paper detail

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

Paula Rodríguez‐Otero, Maialen Sirvent, Ana Pilar González, Esperanza Lavilla, Alfonso García de Coca, José María Arguiñano, Josep M. Martí, Valentín Cabañas, Cristina Motlló, Erik de Cabo, Cristina Encinas, Ilda Murillo, José‐Ángel Hernández‐Rivas, Ernesto Pérez Persona, Felipe Casado, Antònia Sampol, Ricarda García, María Jesús Blanchard, M Fernandez Anguita, Ana Lafuente, Belén Íñigo, Aurelio López, Paz Ribas, Mario Arnao, Roberto Maldonado, Joan Bladé, María‐Victoria Mateos, Juan José Lahuerta, Jesús F. San Miguel

2021Clinical Lymphoma Myeloma & Leukemia11 citationsDOI

Topics & Concepts

PomalidomideLenalidomideMedicineInternal medicineMultiple myelomaDexamethasoneOncologyRefractory (planetary science)CyclophosphamidePopulationSurgeryChemotherapyPhysicsEnvironmental healthAstrobiologyMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsHistone Deacetylase Inhibitors Research